Viridian's Lumvoa Brings In $24.7 Million In Its First Quarter On Sale As Net Loss Widens

More than 100 patients were on the thyroid eye disease drug at the end of September, while selling costs rose to $57.6 million.

Share
Viridian's Lumvoa Brings In $24.7 Million In Its First Quarter On Sale As Net Loss Widens

Viridian Therapeutics, a biotech developing medicines for autoimmune and rare diseases, booked $24.7 million in net sales of its thyroid eye disease drug Lumvoa in the third quarter, its first with a product on the market, the company said Wednesday. The quarterly net loss widened to $101.2 million from $34.6 million a year earlier, according to an 8-K filed with the results.

Launch revenue, bigger bills

More than 100 patients were on Lumvoa at the end of September. The company recorded no product revenue in the third quarter of 2025.

Selling, general and administrative expenses rose to $57.6 million from $24.3 million a year earlier. The company attributed the increase to personnel and professional services supporting Lumvoa and its growing organization.

Research and development spending fell to $70.1 million from $86.3 million. Lower costs for veligrotug and elegrobart clinical studies outweighed added spending on its TSHR and FcRn programs and higher personnel costs.

The loss came to $0.81 per common share, against $0.34 a year earlier. The year-earlier quarter included $70 million of license revenue. Net loss for the first nine months was $333.2 million, versus $222.2 million in the same period of 2025.

A thyroid eye disease specialist

Viridian focuses on thyroid eye disease, a rare autoimmune condition that inflames tissue around the eye. Lumvoa, also called veligrotug, is an intravenous IGF-1R antagonist approved by the FDA for the disease. Its follow-on, elegrobart, is given by injection under the skin.

CEO Steve Mahoney said the early launch "has exceeded expectations." The company also said Medicare's administrator has assigned Lumvoa a permanent billing code, J3242, effective January 1, 2027.

Cash and the next milestones

Cash, cash equivalents and marketable securities were $955.2 million on September 30, up from $874.7 million at the end of 2025. The company said that cash plus future revenue from Lumvoa and, if approved, elegrobart should fund its current plans through profitability.

Viridian expects to submit an FDA license application for elegrobart in the first quarter of 2027. It plans an autoinjector with dosing every four or eight weeks, and says its Lumvoa commercial team can support that launch with limited added investment.

In the fourth quarter, it expects to release phase 1 data for VRDN-008, an FcRn inhibitor, and FcRn development plans. It also expects to start a phase 1 patient trial of VRDN-292, a TSHR antibody, beginning in Graves' disease patients.

Viridian held a webcast on the results at 8:00 a.m. ET Wednesday and has fireside chats set for November 16 at the Jefferies healthcare conference and November 17 at UBS's biopharma conference, both in London.

Sources